A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma .
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- Acronyms MAGNIFY
- Sponsors Celgene Corporation
- 02 Mar 2018 Planned End Date changed from 8 Mar 2023 to 8 Jul 2024.
- 02 Mar 2018 Planned primary completion date changed from 1 Feb 2021 to 8 Apr 2023.
- 21 Jul 2017 Planned number of patients changed from 278 to 500.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History